PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-663

Picking circa $20 to $25m for a full Phase II , in the USA , UK and Australia

They may not need to go the full distance , there is a substantial data read out at 24 weeks , should that first Cohort demonstrate the same "Remarkable" results the first 12 showed then FDA have signaled that FDA approval could be granted on top of the current FDA Orphan Drug Designation..

Picking Trial will be registered in August after the funds have settled , Kick off Australia first as PAA has a Huge Presence in the Australian MND space, the current PI's Mathers and Rowe consult 40% of all MND sufferers in Australia ,coupled to Remarkable results from the Phase I Recruitment in Australia should be swift,,, USA and UK MND Patients are in huge demand for trials,,,

IMHO BP are sitting in the wings monitoring PAA advancements through the trialing continuum, if they discover further positive data or Insights that would make them move swiftly for first mover advantage ,,, its a fineline for BP to be satisfied with solid data but not have the solid data on the SP scoreboard driving up the T/O Price